Immunopotentiator-Loaded Polymeric Microparticles as Robust Adjuvant to Improve Vaccine Efficacy

Zhang, Weifeng; Wang, Lianyan; Yang, Tingyuan; Liu, Yuan; Chen, Xiaoming; Liu, Qi; Jia, Jilei; Ma, Guanghui

doi:10.1007/s11095-015-1666-6

Cited by 11 publications

(17 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To achieve improved safety and potent immune response, nanotechnology is applied in the delivery of multiple TSAs as a cancer vaccine platform. Many nanomaterials have been employed as delivery systems to enhance the stability of multiple TSAs . It was reported that CCM provided multiple TSAs on the surface of nanoparticles to induce the TSA‐specific cytotoxic T lymphocyte (CTL) response and trigger the strong multiantigenic immune response .…”

Section: Introductionmentioning

confidence: 99%

Multiantigenic Nanoformulations Activate Anticancer Immunity Depending on Size

Feng

Wang

et al. 2019

Adv Funct Materials

View full text Add to dashboard Cite

Nanoparticle-adjuvanted cancer vaccines are attracting increasing attention because they can induce an effective anticancer immune response. Singleantigen vaccines are inefficient to inhibit cancer progression due to the heterogeneity of tumors and the antigenicity alteration of tumor-associated antigens. Therefore, the efficient delivery of multiple antigens to antigen-presenting cells is an excellent opportunity for strong anticancer immunity. In this study, three immunoadjuvant-loaded multiantigenic nanoparticles MANPs/R837 with different diameters, i.e., 83, 103, and 122 nm, are prepared through coating of the cancer cell membrane as a source of multiple antigens onto the imiquimod R837-loaded poly(lactic-co-glycolic acid) nanoparticles. The MANP/R837 with a diameter of 83 nm (MANP83/R837) shows the most efficient delivery of the payload to the draining lymph nodes and achieves the best antigen presentation to T lymphocytes. Compared with the other two nanovaccines, MANP83/ R837 has a stronger inhibitory effect on tumor growth and metastasis. In the combination therapy with checkpoint blockade therapy using programmed cell death-1 antibody, MANPs/R837 show effective inhibition against tumor progression, and MANP83/R837 achieves the most exciting effect. Therefore, MANPs/ R837, as a promising therapeutic cancer vaccine, demonstrates great prospects in cancer immunotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Multiantigenic Nanoformulations Activate Anticancer Immunity Depending on Size

Feng

Wang

et al. 2019

Adv Funct Materials

View full text Add to dashboard Cite

show abstract

“…To further investigate the influence of NPE on cell‐mediated immune responses, splenocytes were cultured and analyzed from following aspects: lymphocyte proliferation/activation (the essential premise), cytokines secretion (the magnitude) and memory lymphocytes generation (the duration) [30, 31]. Among them, for PRRS vaccination, although no significant difference in lymphocyte proliferation was observed (Fig.…”

Section: Resultsmentioning

confidence: 99%

Green preparation of hydrogel particles‐in‐emulsions for simultaneous enhancement of humoral and cell‐mediated immunity

Zou

Ngai

et al. 2020

Engineering in Life Sciences

Self Cite

View full text Add to dashboard Cite

Emulsions are one of the most often used vaccine adjuvant formulations. Although they promote high humoral immunity, the induced cellular immunity is often poor, which restrict their application. To enhance the cellular immunity, some researchers have prepared mixed formulations by adding particles into the aqueous phase of emulsions. However, the particle preparation process usually involves the addition and removal of organic reagents, which is environmentally unfriendly and cumbersome. Moreover, the obtained vaccine adjuvant only induces limited cell‐mediated immunity and humoral immunity compared with emulsion‐adjuvanted vaccines. Herein, we developed a green and simple method for fabricating a novel nanoparticles‐in‐emulsions (NPE) formulation. Firstly, a temperature‐sensitive hydrogel was used to prepare particles by self‐solidification without additional crosslinking reagents. Secondly, the white oil was used as organic phase to avoid the particle washing procedures and organic solvent residues. Moreover, the effect of NPE as vaccine adjuvant was evaluated by using two veterinary vaccines as model antigens. NPE showed advantages than the conventional vaccine formulations in inducing both humoral and cellular immunity. This work provides a facile and broadly applicable approach for preparing nanoparticles‐in‐emulsions formulation, and presents an effective adjuvant for enhancing immunity against infectious diseases.

show abstract

“… 54 Previous studies reported good results when immunostimulants were delivered using particulate systems. 19 , 55 , 56 As CpG is a polyanionic oligonucleotide, we designed a cationic NLC to allow its vectorization. Although several studies have described the co-delivery of antigens and immunostimulants in the same particles, Mohsen et al 57 recently demonstrated that they can also be effectively processed by the same APC when carried by different particles, resulting in enhanced immune responses.…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies mentioned similar trends when carriers for both antigens and immunostimulants were used, mostly working with the OVA model. Zhang et al 19 improved antibody titers up to 5-fold by co-delivering OVA and imiquimod in PLGA particles. IFN-γ production was also enhanced in their system, up to 200 pg/mL on average.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Overcoming immunogenicity issues of HIV p24 antigen by the use of innovative nanostructured lipid carriers as delivery systems: evidences in mice and non-human primates

et al. 2018

View full text Add to dashboard Cite

HIV is one of the deadliest pandemics of modern times, having already caused 35 million deaths around the world. Despite the huge efforts spent to develop treatments, the virus cannot yet be eradicated and continues to infect new people. Spread of the virus remains uncontrolled, thus exposing the worldwide population to HIV danger, due to the lack of efficient vaccines. The latest clinical trials describe the challenges associated with developing an effective prophylactic HIV vaccine. These immunological obstacles will only be overcome by smart and innovative solutions applied to the design of vaccine formulations. Here, we describe the use of nanostructured lipid carriers (NLC) for the delivery of p24 protein as a model HIV antigen, with the aim of increasing its immunogenicity. We have designed vaccine formulations comprising NLC grafted with p24 antigen, together with cationic NLC optimized for the delivery of immunostimulant CpG. This tailored system significantly enhanced immune responses against p24, in terms of specific antibody production and T-cell activation in mice. More importantly, the capacity of NLC to induce specific immune responses against this troublesome HIV antigen was further supported by a 7-month study on non-human primates (NHP). This work paves the way toward the development of a future HIV vaccine, which will also require the use of envelope antigens.

show abstract

Immunopotentiator-Loaded Polymeric Microparticles as Robust Adjuvant to Improve Vaccine Efficacy

Abstract: Considering adjuvanticity and safety profiles (PLGA and IMQ, both approved by FDA), we conclude that IMQ-loaded PLGA microparticles are promising robust adjuvant for subunit vaccines.

Cited by 11 publications

References 30 publications

Multiantigenic Nanoformulations Activate Anticancer Immunity Depending on Size

Multiantigenic Nanoformulations Activate Anticancer Immunity Depending on Size

Green preparation of hydrogel particles‐in‐emulsions for simultaneous enhancement of humoral and cell‐mediated immunity

Overcoming immunogenicity issues of HIV p24 antigen by the use of innovative nanostructured lipid carriers as delivery systems: evidences in mice and non-human primates

Contact Info

Product

Resources

About